Clinical Trials

Inclusion Criteria:

• Adults (18-75 years) who have BMI >18 kg/m²

• Able to reside within 75 miles of Mayo Clinic for the duration of the study

• Not currently on treatment (exceptions below) for cardiac, pulmonary, GI, hepatic, renal, hematological, neurological, or endocrine disorders

  • Medications that will be permissible: birth control pill, estrogen and thyroxine replacement.

• Biological sex: men or women.

  • Males of procreative capacity (not surgically sterile) will use an acceptable method of contraception from randomization through 1 month after the study ends. Examples of acceptable contraception for males include abstinence, use of a barrier method, or sterilized or post-menopausal partner

  • Females of child-bearing potential (not surgically sterile or post-menopausal, defined as 12 months without menses) will use an acceptable method of contraception from 1 month prior to randomization (or screening, if earlier) through 1 month after the study ends. Examples of acceptable methods of contraception for females include abstinence, double barrier method, IUD, hormonal contraception, or sterilized partner

Exclusion Criteria:

• Any condition or personal circumstance that, in the opinion of the investigator, renders the subject unlikely or unable to comply with the full study protocol or could interfere with the study assessments

• Any Abdominal surgery (EXCEPTappendectomy, Caesarian section, tubal ligation, cholecystectomy) will exclude participation.

Exclusion Criteria for Phase Two:

• A history of syncope or fainting within the past 6 months

• A known history of orthostatic hypotension

• Any of the following findings during the screening visit:

  • Supine systolic blood pressure (SBP) <110 mmHg

  • Orthostatic decrease in SBP >20 mmHg after 2 minutes of standing or any decrease in blood pressure associated with symptoms of dizziness upon standing

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/06/2026. Questions regarding updates should be directed to the study team contact.